-
Sector Analysis
NewFriedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in FRDA therapeutics. - More than 54,000 diagnosed prevalent cases of FRDA are anticipated in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for FRDA. - The marketed drugs space for FRDA is limited to just two approved drugs, Biogen's Skyclarys (omaveloxolone) is the leading drug in FRDA space. - R&D efforts in the FRDA space are limited, with no pre-registration drugs currently in the...
-
Product Insights
Tauopathies – Drugs In Development, 2023
Global Markets Direct’s, ‘Tauopathies - Drugs In Development, 2023’, provides an overview of the Tauopathies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tauopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Friedreich Ataxia – Drugs In Development, 2023
Global Markets Direct’s, ‘Friedreich Ataxia - Drugs In Development, 2023’, provides an overview of the Friedreich Ataxia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2023
Global Markets Direct’s, ‘Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drugs In Development, 2023’, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) – Drugs In Development, 2023
Global Markets Direct’s, ‘MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) - Drugs In Development, 2023’, provides an overview of the MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) pipeline landscape. The report provides comprehensive information on the therapeutics under development for MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
Chronic Traumatic Encephalopathy (CTE) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Traumatic Encephalopathy (CTE) - Drugs In Development, 2023’, provides an overview of the Chronic Traumatic Encephalopathy (CTE) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Traumatic Encephalopathy (CTE), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Globoid Cell Leukodystrophy (Krabbe Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Globoid Cell Leukodystrophy (Krabbe Disease) - Drugs In Development, 2023’, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Huntington Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Huntington Disease - Drugs In Development, 2023’, provides an overview of the Huntington Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Progressive Supranuclear Palsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Progressive Supranuclear Palsy - Drugs In Development, 2023’, provides an overview of the Progressive Supranuclear Palsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally,...
-
Product Insights
Batten Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Batten Disease - Drugs In Development, 2023’, provides an overview of the Batten Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Batten Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...